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Background: Recent evidence indicates that long noncoding RNAs (lncRNAs) play a critical role in the regulation of
cellular processes, such as differentiation, proliferation and metastasis. These lncRNAs are found to be dysregulated
in a variety of cancers. BRAF activated non-coding RNA (BANCR) is a 693-bp transcript on chromosome 9 with a potential
functional role in melanoma cell migration. The clinical significance of BANCR, and its’ molecular mechanisms controlling
cancer cell migration and metastasis are unclear.
Methods: Expression of BANCR was analyzed in 113 non-small cell lung cancer (NSCLC) tissues and seven NSCLC cell
lines using quantitative polymerase chain reaction (qPCR) assays. Gain and loss of function approaches were used to
investigate the biological role of BANCR in NSCLC cells. The effects of BANCR on cell viability were evaluated by
MTT and colony formation assays. Apoptosis was evaluated by Hoechst staining and flow cytometry. Nude mice
were used to examine the effects of BANCR on tumor cell metastasis in vivo. Protein levels of BANCR targets
were determined by western blotting and fluorescent immunohistochemistry.
Results: BANCR expression was significantly decreased in 113 NSCLC tumor tissues compared with normal
tissues. Additionally, reduced BANCR expression was associated with larger tumor size, advanced pathological
stage, metastasis distance, and shorter overall survival of NSCLC patients. Reduced BANCR expression was found
to be an independent prognostic factor for NSCLC. Histone deacetylation was involved in the downregulation
of BANCR in NSCLC cells. Ectopic expression of BANCR impaired cell viability and invasion, leading to the
inhibition of metastasis in vitro and in vivo. However, knockdown of BANCR expression promoted cell migration
and invasion in vitro. Overexpression of BANCR was found to play a key role in epithelial-mesenchymal transition
(EMT) through the regulation of E-cadherin, N-cadherin and Vimentin expression.
Conclusion: We determined that BANCR actively functions as a regulator of EMT during NSCLC metastasis,
suggesting that BANCR could be a biomarker for poor prognosis of NSCLC.* Correspondence: dewei@njmu.edu.cn; zhaoxiawang88@hotmail.com
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Non-small cell lung cancers (NSCLCs), including adeno-
carcinomas and squamous cell carcinomas, are the pre-
dominant forms of lung cancer and account for the
majority of cancer deaths worldwide [1]. Despite recent
advances in clinical and experimental oncology, the
prognosis of lung cancer remains poor, with a 5-year
overall survival rate of around 11% [2]. A continuing
problem of NSCLC tumorigenesis is the metastasis of
cancer cells, which is the main cause of death in pa-
tients. Thus, a detailed understanding of the mecha-
nisms and molecular pathways activated in metastatic
cells is crucial in identifying new treatment options for
anticancer therapy that target metastasis.
The invasion and metastasis of cancer cells are land-
mark events that involve many changes in cellular be-
havior, and lead to different steps of the metastatic
cascade [3,4]. One of the most crucial steps in the meta-
static cascade is the acquisition of invasive capabilities,
including turnover of cell-cell junctions, degradation of
the cell matrix, and activation of pathways that control
cytoskeletal dynamics in cancer cells. This process is ac-
companied by multiple changes in gene expression, such
as the loss of epithelial markers and a gain in mesenchymal
markers [5,6]. Over the past decade, cell and tumor biolo-
gists have identified the key role of epithelial-mesenchymal
transition (EMT) in cancer cell metastasis, a biological
process where epithelial cells lose their polarity and
undergo transition into a mesenchymal phenotype [7].
EMT enhances tumor cell invasion in response to envir-
onmental triggers, and augments invasive functions by
promoting Rac-dependent mesenchymal migration, and
also contributes to cell growth and survival [8,9]. Import-
ant hallmarks of EMT include the loss of E-cadherin ex-
pression, and increased expression of non-epithelial
cadherins, such as N-cadherin. The loss of E-cadherin
expression is a fundamental event in EMT, and a cru-
cial step in the progression of papillomas to invasive
carcinomas [10]. To date, substantial effort has been
devoted to understanding how EMT is regulated dur-
ing cancer progression. It has been verified that EMT
can be initiated by external signals, such as hepatocyte
growth factor (HGF), epidermal growth factor (EGF),
transforming growth factor (TGF)-b, and fibroblast
growth factor (FGF) [11]. In addition to these signaling
pathways triggered by membrane receptors, recent
studies have highlighted the importance of noncoding
RNAs in the regulation of the epithelial phenotype by
controlling EMT inducers. The miR-200 family has
been found to control EMT by downregulating the ex-
pression of Zeb factors [12]. Furthermore, the long
noncoding RNA (lncRNA) MALAT-1 promoted EMT
by regulating ZEB1, ZEB2 and Slug expression, and ac-
tivating Wnt signaling [13].The lncRNAs are important new members of the
ncRNA family, that are greater than 200 nt, and are un-
able to be translated into proteins. These lncRNAs are
often expressed in a spatial- and temporal-specific pat-
tern. Although very few lncRNAs have been character-
ized in detail, they have been found to participate in a
large range of biological processes, including modulation
of apoptosis and invasion, reprogramming stem cell
pluripotency, and parental imprinting. These findings in-
dicate that lncRNAs play a major role in the regulation
of the eukaryotic genome [14-16]. Researchers have
linked the dysregulation of lncRNAs with diverse human
diseases, in particular cancers [17-19]. Therefore, identi-
fication of cancer-associated lncRNAs and investigation
of their molecular and biological functions in controlling
EMT are important in understanding the molecular biol-
ogy of NSCLC metastasis and progression.
BRAF-activated non-coding RNA (BANCR), an 693-bp
lncRNA on chromosome 9 was firstly found by Ross J.
Flockhart et.al via RNA-seq screen for transcripts affected
by the expression of the oncogene BRAFV600E. BANCR is
overexpressed in melanoma cells and crucial for melanoma
cell migration [20]. In this study, we investigated the effects
of BANCR expression on NSCLC cell phenotypes in vitro
and in vivo. Moreover, we also showed that alteration of
BANCR expression can influence E-cadherin, N-cadherin
and Vimentin protein levels, which indicated that BANCR
affected NSCLC cells invasion and metastasis partly via
epithelial-mesenchymal transition. This study advances our
understanding of the role of lncRNAs, such as BANCR as a
regulator of pathogenesis of NSCLC and facilitate the devel-
opment of lncRNA-directed diagnostics and therapeutics.
Results
BANCR expression was downregulated and correlated
with poor prognosis of NSCLC
BANCR expression levels were investigated in 113 paired
NSCLC samples and adjacent histologically normal tissues
using quantitative polymerase chain reaction (qPCR) as-
says. BANCR expression was significantly downregulated
(P < 0.01) in 79% (89/113) of cancerous tissues compared
with normal tissues (Figure 1A). BANCR expression levels
in NSCLC were significantly correlated with tumor size
(p = 0.001), advanced pathological stage (p < 0.001), and
lymph node metastasis (p = 0.001). However, BANCR ex-
pression was not associated with other parameters such as
gender (p = 0.232) and age (p = 0.616) in NSCLC (Table 1).
The clinical data for all patients were summarized in
Additional file 1: Table S1.
Association of BANCR expression with patients’ survival
Kaplan-Meier survival analysis was conducted to investi-
gate the correlation between BANCR expression and
NSCLC patient prognosis. According to relative BANCR
Figure 1 Relative BANCR expression in NSCLC tissues and its clinical significance. (A) Relative expression of BANCR in NSCLC tissues (n = 113)
compared with corresponding non-tumor tissues (n = 113). BANCR expression was examined by qPCR and normalized to GAPDH expression.
Results were presented as the fold-change in tumor tissues relative to normal tissues. (B) BANCR expression was classified into two groups.
(C, D) Kaplan–Meier disease-free survival and overall survival curves according to BANCR expression levels. *P < 0.05, **P < 0.01.
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classified into two groups: the high BANCR group (n = 53,
fold-change ≤ 4); and the low BANCR group (n = 60, fold-
change ≥4) (Figure 1B). With respect to progression-free
survival (PFS), this was 35.3% for the high BANCR group,
and 17.2% for the low BANCR group. Median survival
time for the high BANCR group was 31 months, and 16
months for the low BANCR group (Figure 1C). The over-
all survival rate over 3 years for the high BANCR group
was 46%, and 27.5% for the low BANCR group. Median
survival time for the high BANCR group was 32 months,
and 18 months for the low BANCR group (Figure 1D).
Univariate analysis identified three prognostic factors:
lymph node metastasis; TNM stage; and BANCR expres-
sion level. Other clinicopathological features such as gender
and age were not statistically significant prognosis factors
(Table 2). Multivariate analysis of the three prognosis
factors confirmed that a low BANCR expression level wasan independent predictor of poor survival for NSCLC
(p = 0.031), in addition to TNM stage (p = 0.038) (Table 2).
Histone deacetylation is involved in the downregulation
of BANCR
Expression levels of BANCR in NSCLC cell lines were de-
termined by qPCR. Compared with that in 16HBE cells,
relative expression levels of BANCR were reduced in
NSCLC cells (Figure 2A). Because of the different expres-
sion patterns for BANCR in NSCLC and melanomas, we
investigated the mechanisms controlling tissue-specific
expression of BANCR. We analyzed the promoter region
of BANCR, and found there were no CpG islands (data
not shown). Histone protein modification was thought to
play an important role in the transcription of lncRNAs;
however, knockdown of two core subunits of polycomb
repressive complex 2 (SUZ12 and EZH2) had no influence
on BANCR expression (Additional file 2: Figure S1A).
Table 1 Correlation between BANCR expression and















Squamous cell carcinoma 30(56.6) 38(63.3)
Adenocarcinoma 23(43.4) 22(36.7)
TNM Stage <0.001*
Ia + Ib 25(47.2) 9(15.0)










Never Smokers 14(35.8) 24(40.0)
* Overall P < 0.05.
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in SPC-A1 and A549 cells, following treatment with the
histone deacetylase (HDAC) inhibitor trichostatin A
(TSA) (Figure 2B). We sought to determine whether re-






Histological subtype 0.982 0.738-1.307
Chemotherapy 0.787 0.587-1.055
Tumor size 1.233 0.926-1.640
Lymph node metastasis 0.424 0.235-0.764
TNM stage (I vs. II or IIIa) 0.320 0.149-0.685
BANCR expression 0.367 0.201-0.669
HR, hazard ratio; 95 % CI, 95 % confidence interval, * Overall P < 0.05.anti-HDAC1 and HDAC3 siRNAs were transfected into
NSCLC cells, and HDAC1 and HDAC3 expression was
significantly decreased (Figure 2C). Expression levels of
BANCR were significantly upregulated in cells transfected
with si-HDAC3. Transfection with the scrambled siRNA or
si-HDAC1 did not induce BANCR expression (Figure 2D
and E). Moreover, the HDAC3 expression was upregulated
in NSCLC cells and negatively correlated with BANCR ex-
pression (Additional file 2: Figure S1B). Furthermore,
NSCLC cells were treated with RGFP966, which is an sele-
tive inhibitor for HDAC3 with an IC50 of 0.08μM and no
effective inhibition of other HDACs at concentrations up
to 15μM. The results of qPCR showed that the expression
of BANCR was upregulated in NSCLC cells after treated
with RGFP966 when compared with control cells
(Additional file 2: Figure S1C). These data indicate that
HDAC3 knockdown induced BANCR increase may be
due to the inhibition of HDAC3 enzymatic activity.
BANCR inhibits NSCLC cell viability and induces apoptosis
To assess the biological role of BANCR in NSCLC, we in-
vestigated the effects of BANCR over-expression on the
viability and apoptosis of SPCA1 or A549 cells. Our qPCR
results revealed that BANCR expression was significantly
upregulated compared with that in control cells (Figure 3A).
MTT assay results showed that the growth of SPC-A1 and
A549 cells transfected with pCDNA-BANCR was impaired
compared with that for control cells (Figure 3B and C).
Colony formation assay results revealed that clonogenic
survival was inhibited following overexpression of BANCR
in SPC-A1 and A549 cells (Figure 3D). Flow cytometry
analysis of SPC-A1 and A549 cells showed that upregula-
tion of BANCR expression promoted apoptosis in compari-
son with that in control cells (Figure 3E).
BANCR inhibits migration and invasion of NSCLC cells
The wound healing assay results showed that cells trans-
fected with pCDNA-BANCR resulted in a slower closingal in NSCLC patients (n = 113)
Multivariate analysis







0.004* 0.577 0.311-1.071 0.081
0. 003* 0.431 0.195-0.954 0.038*
0. 001* 0.496 0.262-0.938 0.031*
Figure 2 Histone deacetylation is involved in BANCR downregulation. (A) BANCR expression levels of NSCLC cell lines (A549, SPC-A1, H1299,
H1650, H1975 and SK-MES-1) compared with that in normal human bronchial epithelial cells (16HBE). (B) qPCR analysis of BANCR expression levels
following the treatment of SPC-A1 and A549 cells with TSA. (C) qPCR analysis of HDAC2 and HDAC3 expression levels following the treatment of
SPC-A1 and A549 cells with si-HDAC2 or si-HDAC3.(D, E) qPCR analysis of BANCR expression levels following the treatment of SPC-A1 and A549
cells with si-HDAC1 and si-HDAC3.
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(Figure 4A and B). We evaluated cancer cell invasion
through matrigel, and migration through transwells. In-
creased BANCR expression levels impeded the migration
of SPC-A1 and A549 cells by approximately 64% com-
pared with controls (Figure 4C and D). Similarly, inva-
sion of SPC-A1 and A549 cells was also reduced by 59%
following upregulation of BANCR expression.
Knockdown of BANCR expression promotes NSCLC cells
invasion
To determine whether inhibition of BANCR expression
could promote NSCLC cells viability and invasion, we
performed targeted knockdown of BANCR expression
using RNA interference (RNAi) in A549 cells (Figure 5A).
MTT assays revealed that downregulation of BANCR ex-
pression did not affect cell viability (data not shown).
However, decreased BANCR expression levels promoted
A549 cell migration and invasion in vitro (Figure 5B).
BANCR suppresses NSCLC cell metastasis in vivo
To validate the effects of BANCR on the metastasis of
NSCLC cells in vivo, SPCA1 cells stably transfected with
pCDNA-BANCR were injected into nude mice. Meta-
static nodules on the surface of lungs were counted after
7 weeks. Ectopic overexpression of BANCR resulted in areduction of the number of metastatic nodules com-
pared with those in the control group (Figure 5C). This
difference was further confirmed following examination
of the entire lungs, and through hematoxylin and eosin
(HE) staining of lung sections (Figure 5D). Our in vivo
data complemented the results of functional in vitro
studies involving BANCR.
BANCR influences NSCLC cell EMT
We conducted qPCR and western blotting assays to detect
the expression of EMT-induced markers (E-cadherin,
N-cadherin and Vimentin) in cells over-expressing BANCR.
Our findings showed that increased BANCR expression
levels induced E-cadherin expression, while decreased
N-cadherin, Vimentin and MMP-2 expression (Figure 6A).
Simultaneously, upregulation of BANCR expression led to
decreased SNAIL1, SNAIL2, and SIP1 expression (Figure 6B).
Western blotting and immunofluorescence analysis
also revealed that enhanced BANCR expression stimu-
lated E-cadherin expression and reduced Vimentin ex-
pression in NSCLC cells (Figure 6B and C).
Discussion
Recent evidence has shown that ncRNAs play an im-
portant role in cancer pathogenesis, and could provide
new insights into the biology of this disease [21,22].
Figure 3 Effects of BANCR on NSCLC cell viability and apoptosis in vitro. (A) SPC-A1 and A549 cells were transfected with pCDNA-BANCR.
(B, C) MTT assays were used to determine the cell viability for pCDNA-BANCR-transfected SPC-A1 and A549 cells. Values represented the mean ± s.d.
from three independent experiments. (D) Colony-forming assays were conducted to determine the proliferation of pCDNA-BANCR-transfected SPC-A1
and A549 cells. (E) Apoptosis was determined by flow cytometry. UL, necrotic cells; UR, terminal apoptotic cells; LR, early apoptotic cells. *P < 0.05
and **P < 0.01.
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to the forefront of ncRNA research in NSCLC. However,
lncRNAs in NSCLC are still an emerging field, with only a
handful of lncRNAs involved in NSCLC tumorigenesis.
One of these lncRNAs is metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1). MALAT1,
also known as NEAT2 (nuclear-enriched abundant
transcript 2), is a highly conserved nuclear lncRNA
and a predictive marker for metastasis development in
lung cancer [23].
In this study, we found that the expression of another
lncRNA, BANCR, was significantly downregulated in
NSCLC tissues. Specifically, BANCR expression was sig-
nificantly lower at the later stages of tumor develop-
ment, and in tumors that had undergone extensive
metastasis. Moreover, the overall survival time of pa-
tients with lower BANCR expression levels was signifi-
cantly shorter than that for patients with higher BANCR
expression levels. Our results indicate that BANCR ex-
pression provided a significant, independent predictive
value for TNM stage (P = 0.038). We demonstrated that
upregulation of BANCR expression led to the significant
inhibition of cell viability, migration, invasion, and pro-
motion of apoptosis. Knockdown of BANCR expressionpromoted cell migration and invasion. BANCR induced
cell apoptosis may be partly via P53, which could contrib-
ute to the less cells in migration and invasion; however,
the impaired migration and invasion ability is the main
reason which could be supported by wound-healing assay.
Moreover, increased BANCR expression levels resulted in
a significant reduction in the number of metastatic nod-
ules on the lungs in vivo. These findings suggest that
BANCR plays a direct role in the modulation of cell me-
tastasis and NSCLC progression, and may be useful as a
novel prognostic or progression marker for NSCLC.
Tumor development and progression is precisely regu-
lated by several subsets of genes that act by either silen-
cing tumor suppressor genes or activating oncogenes
[24]. Tumor suppressor genes can negatively regulate
cell proliferation by inducing growth arrest and inhibit-
ing cell invasion. In cancer cells, tumor suppressor genes
are usually silenced by genetic or epigenetic alterations
[25]. Whether epigenetic regulatory factors, such as his-
tone acetylation or DNA methylation, manipulate the
expression of lncRNAs remains unclear. Hypermethyla-
tion of the promoter or the intergenic differentially
methylated region has been found to contribute to re-
duced lncRNA MEG3 expression in tumors, indicating
Figure 4 Effects of BANCR on NSCLC migration and invasion in vitro. SPC-A1 and A549 cells were transfected with pCDNA-BANCR.
(A, B) Wound-healing assays were used to investigate the migratory ability of NSCLC cells. (C, D) Transwell assays were used to investigate
the changes in migratory and invasive abilities of NSCLC cells. *P < 0.05 and **P < 0.01.
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Figure 5 Effects of BANCR overexpression on tumor metastasis in vivo. (A) BANCR expression levels were determined by qPCR following the
treatment of A549 cells with si-BANCR. (B) Transwell assays were conducted to determine the migratory and invasive abilities of si-BANCR-transfected
A549 cells. Analysis of an experimental metastasis animal model was performed by injecting BANCR-overexpressing SPC-A1 cells into nude mice.
(C) Lungs from mice in each experimental group, with the numbers of tumor nodules on lung surfaces were shown. (D) Visualization of the
entire lung, and HE-stained lung sections. **P < 0.01.
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sion of these genes [26,27]. Our findings highlight that
histone acetylation is a key factor in controlling lncRNA
BANCR expression. These results, along with those from
a recent study [28], highlight the role of epigenetics in
regulating lncRNA transcription.
To explore the molecular mechanism through which
BANCR contributes to the invasion and metastasis of
NSCLC, we investigated potential target proteins in-
volved in cell motility and matrix invasion. Hallmarks of
EMT are the loss of E-cadherin expression, and aberrant
expression of N-cadherin and Vimentin [29-32]. There-
fore, we determined the protein levels of these EMT-
induced markers following BANCR overexpression. Our
results indicated that inhibitory effects on cell migrationand invasion were associated with EMT. Matrix metallo-
proteases (MMPs) are also important to many aspects of
biology, ranging from cell proliferation, differentiation
and remodeling of the extracellular matrix (ECM), to
vascularization and cell migration. Upregulation of BANCR
expression in NSCLC cells led to a significant decrease in
MMP2 protein levels. Our findings demonstrated that
BANCR mediated NSCLC cell migration, invasion and me-
tastasis suppression, which possibly also affected EMT.
As a central differentiation process, EMT allows for re-
modeling of tissues during the early stages of embryo-
genesis, and is implicated in the promotion of tumor cell
invasion and metastasis [7,33]. It has been proposed,
and supported by many studies, that EMT could be a
potent mechanism for promoting the detachment of
Figure 6 BANCR overexpression suppresses NSCLC cell invasion and metastasis by affecting EMT. (A, B) Analysis of E-cadherin, N-cadherin,
Vimentin, MMP-2, MMP-9, SNAIL1, SNAIL2, TWIST and SIP1 expression in A549 cells treated with pCDNA-BANCR. (C,D) Analysis of E-cadherin and
Vimentin expression in A549 cells treated with pCDNA-BANCR by western blot and immunofluorescence. All experiments were performed in triplicate
with three technical replicates. *P < 0.05 , **P < 0.01.
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cells that undergo EMT is increased expression levels of
N-cadherin and Vimentin, and a loss of E-cadherin ex-
pression. Importantly, EMT has been reported to be as-
sociated with poor clinical outcome in NSCLC [34,35].
Therefore, lncRNAs as regulators of EMT might be suit-
able candidates for intervention in the treatment of
cancer.
Although only a small number of functional lncRNAs
have been well characterized to date, they have been shown
to regulate gene expression at various levels, including chro-
matin modification, transcription and post-transcriptional
processing. Hox transcript antisense intergenic RNA(HOTAIR) is one of the most studied lncRNAs in-
volved in chromatin modification, which can target
PRC2 genome-wide to alter H3K27 methylation and
gene expression patterns [22]. A muscle-specific lncRNA,
linc-MD1 may function as competing endogenous RNAs
(ceRNAs) to sponge miRNAs, thereby modulating the de-
repression of miRNA targets and impose an additional
level of post-transcriptional regulation [36]. Here, al-
though we observed BANCR overexpression induced
NSCLC cells apoptosis and regulate EMT phenotype, the
possible mechanisms that underlie such regulatory behav-
iors still remain to be fully understood. Further investiga-
tion of BANCR molecular and biological functions in
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standing the molecular biology of NSCLC metastasis and
progression.
Conclusions
The expression of BANCR was significantly decreased in
NSCLC tissues, suggesting that its downregulation may
be a negative prognostic factor for NSCLC patients, and
indicative of poor survival rates and a higher risk for
cancer metastasis. We showed that BANCR possibly reg-
ulates the invasive and metastatic ability of NSCLC cells,
partially through regulation of EMT. Our findings further
the understanding of NSCLC pathogenesis and develop-
ment, and facilitate the development of lncRNA-directed
diagnostics and therapeutics against cancers. However, the
molecular mechanisms through which BACNR regulates
EMT requires further investigation.
Methods
Tissue collection
We obtained 113 paired NSCLC and adjacent non-tumor
lung tissues from patients who underwent surgery at
Jiangsu Province Hospital between 2008 and 2010, and
were diagnosed with NSCLC (stages I, II, and III) based
on histopathological evaluation. Clinicopathological char-
acteristics, including tumor-node-metastasis (TNM) sta-
ging, were recorded. No local or systemic treatment was
conducted in these patients before surgery. All collected
tissue samples were immediately snap-frozen in liquid ni-
trogen and stored at –80°C until required. Our study was
approved by the Research Ethics Committee of Nanjing
Medical University, China. Written informed consent was
obtained from all patients.
Cell lines
Five NSCLC adenocarcinoma cell lines (A549, SPC-A1,
NCI-H1975, NCI-H1299, and NCI-H1650), a NSCLC
squamous carcinomas cell line (SK-MES-1), and a normal
human bronchial epithelial cell line (16HBE) were pur-
chased from the Institute of Biochemistry and Cell Biology
of the Chinese Academy of Sciences (Shanghai, China).
A549, SK-MES-1, NCI-H1975, NCI-H1299, NCI-H1650
and 16HBE cells were cultured in RPMI 1640; SPC-A1
cells were cultured in DMEM (GIBCO-BRL) medium sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 mg/ml streptomycin (Invitrogen,
Carlsbad, CA, USA) at 37ºC/5% CO2.
RNA extraction and qPCR assays
Total RNA was isolated with TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. Total RNA
(500 ng) was reverse transcribed in a final volume of 10
μl using random primers under standard conditions for
the PrimeScript RT reagent Kit (TaKaRa, Dalian, China).We used the SYBR Premix Ex Taq (TaKaRa, Dalian,
China) to determine BANCR expression levels, following
the manufacturer’s instructions. Results were normalized
to the expression of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH). The specific primers used are
presented in Additional file 3: Table S2. The qPCR as-
says were conducted on an ABI 7500, and data col-
lected with this instrument. Our qPCR results were
analyzed and expressed relative to threshold cycle
(CT) values, and then converted to fold changes.
Plasmid generation
The BANCR sequence was synthesized and subcloned
into the pCDNA3.1 (Invitrogen, Shanghai, China) vector.
Ectopic expression of BANCR was achieved through
pCDNA-BANCR transfection, with an empty pCDNA3.1
vector used as a control. The expression levels of BANCR
were detected by qPCR.
Cell transfection
Plasmid vectors (pCDNA3.1-BANCR and pCDNA3.1)
for transfection were prepared using DNA Midiprep or
Midiprep kits (Qiagen, Hilden, Germany), and transfected
into SPC-A1 or A549 cells. The siRNAs si-HDAC1, si-
HDAC3, si-BANCR or si-NC were transfected into SPC-
A1 or A549 cells (Additional file 3: Table S2). A549 and
SPC-A1 cells were grown on six-well plates to confluency
and transfected using Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s instructions. At 48 h post-
transfection, cells were harvested for qPCR or western blot
analysis.
Cell viability assays
Cell viability was monitored using a Cell Proliferation
Reagent Kit I (MTT) (Roche Applied Science). The A549
cells transfected with si-BANCR (3000 cells/well), and
A549 or SPC-A1 cells transfected with pCDNA-BANCR
were grown in 96-well plates. Cell viability was assessed
every 24 h following the manufacturer’s protocol. All ex-
periments were performed in quadruplicate. For colony
formation assays, pCDNA-BANCR-transfected SPC-A1
or A549 cells (n = 500) were placed in a 6-well plates and
maintained in media containing 10% FBS. The medium
was replaced every 4 days; after 14 days, cells were fixed
with methanol and stained with 0.1% crystal violet
(Sigma-Aldrich). Visible colonies were then counted. For
each treatment group wells were assessed in triplicate.
Flow cytometry analysis of apoptosis
SPC-A1 and A549 cells were harvested at 48 h post-
transfection by trypsinization. After staining with FITC-
Annexin V and propidium iodide, cells were analyzed
by flow cytometry (FACScan; BD Biosciences) using
CellQuest software (BD Biosciences). Cells were discriminated
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apoptotic cells. The ratio of early apoptotic cells was
compared to that for controls from each experiment.
All samples were assayed in triplicate.Wound-healing assay
For the wound-healing assay, 3 × 105 cells were seeded
in 6-well plates, cultured overnight, and transfected with
pCDNA-BANCR or the control vector. Once cultures
reached 85% confluency, the cell layer was scratched
with a sterile plastic tip and washed with culture
medium, then cultured for 48 h with medium containing
1% FBS. At different time points, images of the plates
were acquired using a microscope. The distance between
the two edges of the scratch was measured using Digimi-
zer software system.Cell migration and invasion assays
For the migration assays, at 48 h post-transfection, 5 × 104
cells in serum-free media were placed into the upper
chamber of an insert (8-μm pore size; Millipore). For the
invasion assays, 1 × 105 cells in serum-free medium were
placed into the upper chamber of an insert coated with
Matrigel (Sigma-Aldrich). Medium containing 10% FBS
was added to the lower chamber. After incubation for 24 h,
the cells remaining on the upper membrane were removed
with cotton wool. Cells that had migrated or invaded
through the membrane were stained with methanol and
0.1% crystal violet, imaged, and counted using an IX71
inverted microscope (Olympus, Tokyo, Japan). Experi-
ments were independently repeated three times.Tail vein injections into athymic mice
Athymic male mice (4-weeks-old) were purchased from
the Animal Center of the Chinese Academy of Science
(Shanghai, China) and maintained in laminar flow cabi-
nets under specific pathogen-free conditions. SPC-A1
cells transfected with pCDNA-BANCR or the empty
vector were harvested from 6-well plates, washed with
phosphate-buffered saline (PBS), and resuspended at
2 × 107 cells/ml. Suspended cells (0.1 ml) were injected
into the tail veins of 9 mice, which were sacrificed 7 weeks
after injection. The lungs were removed and photographed,
and visible tumors on the lung surface were counted.
This study was carried out in strict accordance with the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. Our protocol was ap-
proved by the Committee on the Ethics of Animal Experi-
ments of Nanjing Medical University (Permit Number:
200933). All surgery was performed under sodium pento-
barbital anesthesia, and all efforts were made to minimize
suffering [37].Western blotting analysis
Cells were lysed using RIPA protein extraction reagent
(Beyotime, Beijing, China) supplemented with a protease
inhibitor cocktail (Roche, CA, USA) and phenylmethyl-
sulfonyl fluoride (Roche). The concentration of proteins
was determined using the Bio-Rad protein assay kit.
Protein extracts (50 μg) were separated by 10% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
then transferred to nitrocellulose membranes (Sigma) and
incubated with specific antibodies. ECL chromogenic
substrate was used to visualize the bands and the in-
tensity of the bands was quantified by densitometry
(Quantity One software; Bio-Rad), with GAPDH used
as a control. Antibodies (1:1000 dilution) against E-cadherin
and N-cadherin were purchased from BD. Antibodies
against vimentin, MMP-2, and MMP-9 were purchased
from Cell Signaling Technology (MA, USA).
Fluorescence immunohistochemistry
Cells were fixed in 4% paraformaldehyde following a stand-
ard protocol. Mouse anti-E-cadherin and -N-cadhherin
polyclonal antibodies (1:100; BD) were used as primary
antibodies, with TRITC-labeled anti-Rabbit IgG (1:200;
Sigma) used as a secondary antibody. Sections were
mounted onto slides using Gel Mount Aqueous Mounting
Medium (G0918, Sigma) and examined with an Olympus
BX51 microscope (Olympus Optical, Tokyo, Japan).
Statistical analysis
Student’s t-test (2-tailed), one-way ANOVA, and the
Mann–Whitney U test were used to analyze data, along
with SPSS 16.0 (IBM, IL, USA). P-values of less than
0.05 were considered statistically significant.
Additional files
Additional file 1: Table S1. Clinicopathological characteristics and
BANCR expression of 113 patient samples of NSCLC.
Additional file 2: Figure S1. Effects of EZH2, SUZ12 and HDAC3 on
BANCR expression. (A) Analysis of BANCR expression levels by qPCR
following treatment of SPC-A1 and A549 cells with si-EZH2 and SUZ12.(B)
Analysis of HDAC3 mRNA expression levels by qPCR in NSCLC cell lines.
HDAC3 expression was upregulated more significantly in SPC-A1, H1650
and H1975 cells compared with 16HBE cells. (C) A549 and SPC-A1 cells
were treated with selective HDAC3 inhibitor RGFP966 (dissolved in DMSO)
at concentrations of 15μM for 24 hours. Analysis of BANCR expression
levels by qPCR following treatment of SPC-A1 and A549 cells with
RGFP966. *P < 0.05, N.S. no significant.
Additional file 3: Table S2. Sequence of primers and siRNA.
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